In November 2025, US President Donald Trump announced transformative actions aimed at lowering prescription drug costs and securing the pharmaceutical supply chain in the United States. This initiative includes the implementation of Most Favored Nation (MFN) pricing deals, which are designed to ensure that US consumers pay no more for drugs than the lowest price paid by other countries. Such pricing strategies are expected to significantly impact the cost structure of pharmaceuticals, ultimately benefiting healthcare providers and patients alike.
The context of this announcement is rooted in the ongoing challenges within the US healthcare system, where rising drug prices have been a focal point of concern for both policymakers and the public. By addressing these issues through MFN pricing, the administration seeks to enhance affordability while simultaneously encouraging domestic manufacturing investments. This dual approach aims to bolster the resilience of the pharmaceutical supply chain, which has faced disruptions in recent years.
The implications of these changes are profound for B2B professionals in the pharmaceutical sector, particularly those in regulatory, QA/QC, CMC, sourcing, and portfolio management roles. As pricing structures evolve, companies will need to adapt their strategies to align with new regulations and market expectations. Furthermore, increased domestic manufacturing could lead to shifts in sourcing strategies and supply chain dynamics, necessitating a proactive response from industry stakeholders.
Use the database as your supply chain compass →
